Skip to content
Search for:
About us
Our Science
miRNA therapeutics
Platform
IP & Publications
Pipeline
News
Careers
Contact
Search for:
Loading...
News
Breakthrough
miRNA therapeutics
tackling cancer
News releases
2021
InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3
December 2
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board
October 19
InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board
October 12
GBR Connect Series - Interview with Roel Schaapveld, InteRNA Technologies - US Pharma & Biopharma
September 16
InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy – Nucleic Acids and Oncotarget
March 24
InteRNA and the renewed interest in RNA therapeutics in the March 2021 edition of MedNous
March 21
InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government
March 11
InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
February 16
InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M
February 9
InteRNA in de Kerstbijlage van het Algemeen Dagblad d.d. 17 december 2020: Nieuwe vorm van immunotherapie helpt bij de bestrijding van kanker.
January 6
Archives
2020
CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial
May 20
Recently a short movie about InteRNA and it’s lead compound for the treatment of cancer was broadcasted in the RTL4/RTLZ program “Zo kan het ook”. Watch the video with the latest news here
May 18
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
May 6
InteRNA steunt de campagne Innovaties in Oncologie van @Mediaplanet. Leer meer over verschillende innovaties in oncologie zoals immuuntherapieën van thought leaders, zoals Ton Schumacher online of in de New Scientist (24 maart 2020)
March 25
2019
InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting
October 31
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting
October 31
InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy
May 15
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
March 25
2018
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting
October 1
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
April 18
InteRNA to Present Preclinical Proof-of-Concept Data on Lead microRNA Candidate INT-1B3 at 2018 AACR Annual Meeting
March 27
New Journal of Neuroscience paper shows that our functional screening platform for miRNA drug candidates works also nicely outside Oncology
February 21
2017
New Cancer Research paper on the Mode of Action of one of our proprietary miRNA drug candidates for the treatment of epithelial cancers by UMC radboud icw InteRNA Technologies under our STW grant program
February 28
2016
InteRNA builds Management Team for next stage of development
January 12
2015
InteRNA Technologies secures final extension Series A financing and strengthens its Supervisory Board
October 29
2014
InteRNA Technologies, UCB and University of Bonn to collaborate on the role of microRNAs in neurodegenerative disease
January 10
2013
MiRacle Consortium led by InteRNA Technologies and VU University Medical Center
November 4
InteRNA Technologies partner in €11.5 Million EU Framework Program 7
September 18
InteRNA Technologies also receives notice of allowance for its melanoma lead compound miRNA-3157 in Australia
September 16
SomantiX B.V. and InteRNA Technologies B.V. obtain a MIT R&D collaboration grant
September 5
InteRNA's R&D collaboration partner UMC St. Radboud receives grant from Stichting voor de Technische Wetenschappen
July 17
2012
InteRNA Technologies receives notice of allowance for miRNA sequences of its lead pre-clinical product
October 15
InteRNA Technologies B.V. announces full consolidation of its subsidiary InteRNA Genomics B.V. as of July 1, 2012
July 1
2011
InteRNA Technologies announces establishment of Supervisory Board
November 21
Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics
September 12
InteRNA Technologies Strengthens its R&D Team Nijmegen/Utrecht (the Netherlands)
April 29
2010
InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands)
November 16
InteRNA Technologies announces establishment of Scientific Advisory Board Utrecht (the Netherlands)
July 8
2009
InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways
November 2
New small and medium enterprises join TIPharma by signing two new projects
July 6
InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
April 22
2008
InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery
November 17
InteRNA Technologies Joins European SIROCCO Consortium to Study RNA Silencing
November 6
InteRNA Technologies and VU University Medical Center to Develop microRNA-based Diagnostics and Therapeutics for Cancer
October 10
Page load link
Go to Top